尔康制药(300267) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 275,789,340.20, a decrease of 49.57% compared to CNY 546,925,468.79 in the same period last year[4]. - Net profit attributable to shareholders was CNY 2,901,461.74, down 88.87% from CNY 26,078,945.63 year-on-year[4]. - Operating income decreased by CNY 27,113,620.00, or 49.57%, primarily due to delays in the import of raw materials and a decline in sales of pharmaceutical intermediates[10]. - Total operating revenue for Q1 2024 was ¥275,789,340.20, a decrease of 49.6% compared to ¥546,925,468.79 in the same period last year[26]. - Net profit for Q1 2024 was -¥285,701.09, a significant decline from ¥20,455,494.16 in Q1 2023[27]. - The company reported a comprehensive income total of -¥34,221,597.97 for Q1 2024, compared to -¥2,360,585.01 in the previous year[28]. - Basic and diluted earnings per share for Q1 2024 were both ¥0.0014, down from ¥0.0126 in Q1 2023[28]. Cash Flow - The net cash flow from operating activities improved to CNY 10,699,220.82, a significant increase of 108.68% compared to a negative cash flow of CNY -123,203,775.36 in the previous year[4]. - Cash inflows from operating activities totaled ¥296,255,671.71, compared to ¥610,092,589.46 in Q1 2023, reflecting a decrease of 51.5%[29]. - Cash outflows from operating activities were ¥285,556,450.89, down from ¥733,296,364.82 year-over-year[29]. - The net cash flow from investment activities was -200,634,546.56 CNY, compared to -49,235,087.06 CNY in the previous year[30]. - Cash inflow from financing activities totaled 307,844,027.78 CNY, significantly higher than 65,550,895.10 CNY in the same period last year[30]. - The net cash flow from financing activities was 154,886,859.29 CNY, contrasting with a negative flow of -170,401,976.48 CNY in the previous year[30]. - The net increase in cash and cash equivalents was -40,894,504.26 CNY, compared to -345,705,692.65 CNY in the previous year[30]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,461,856,952.50, a slight decrease of 0.31% from CNY 5,479,068,857.74 at the end of the previous year[4]. - The total current liabilities rose to RMB 620,227,763.04 from RMB 603,301,011.78, representing an increase of approximately 2.5%[23]. - The total liabilities amounted to ¥685,980,422.61, an increase from ¥669,054,673.06 in the previous quarter[27]. - The company's cash and cash equivalents decreased to RMB 535,043,558.26 from RMB 744,349,595.87, reflecting a decline of approximately 28.2%[22]. Investments and Research - The company experienced a 307.50% increase in cash outflow from investing activities, totaling CNY -20,063,450.00, mainly due to increased financial investment outflows[12]. - The company reported a total of 7 new authorized patents related to traditional Chinese medicine production processes and equipment during the reporting period[21]. - A new bronchodilator and cough relief injection product has been submitted for registration and is currently in the inspection phase[21]. - The company is actively advancing the research of an anti-heart failure drug and has submitted supplementary materials for pre-listing communication[21]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 48,671, with the largest shareholder holding 41.38% of the shares[13]. Accounting and Auditing - The company did not undergo an audit for the first quarter report[31]. - The company implemented new accounting standards starting in 2024, affecting the financial statements[31].